本文へ移動
cccskills
無料GitHub で公開

es-cushing-pituitary-directed-medical-treatments

This skill suggests pituitary-directed medical treatments (e.g., cabergoline, pasireotide) for patients with Cushing's disease who are not surgical candidates or have persistent disease after transsphenoidal surgery. Use when a CD patient cannot undergo surgery or has residual disease post-TSS; triggers include "not a surgical candidate", "persistent disease after TSS", "ongoing hypercortisolism despite prior surgery".

dromlakhani/MD2SKILL
インストール方法を見る

含まれるファイル（1）

  • SKILL.md3.1 KB

SKILL.md（原文）

インストールする前に、エージェントに与えられる指示の中身を確認できます。

Pituitary-Directed Medical Treatments for Patients With Cushing's Disease Who Are Not Surgical Candidates or Have Persistent Disease After TSS

STEP 1 — Gather Information

Confirm diagnosis of Cushing's disease (ACTH-dependent, pituitary source) via biochemical testing (elevated UFC, late-night salivary cortisol, dexamethasone suppression) and pituitary MRI showing adenoma; assess surgical candidacy (comorbidities, patient preference, surgical risk); document prior TSS outcome and current UFC or late-night salivary cortisol levels; evaluate for comorbidities that affect drug choice (e.g., diabetes, hyperglycemia risk).

STEP 2 — Rule In / Rule Out

If patient has confirmed CD and is either not a surgical candidate or has persistent/recurrent disease after TSS (elevated UFC or late-night salivary cortisol post-TSS), proceed; otherwise, consider primary surgery or other definitive therapy.

STEP 3 — Classify or Stratify

Stratify by baseline UFC severity and comorbidities: mild hypercortisolism (UFC <2× upper limit normal) and no significant hyperglycemia risk → consider cabergoline; moderate-to-severe hypercortisolism (UFC ≥2×) or diabetes/glucose intolerance → consider pasireotide; if prior failure of one agent, consider combination therapy (e.g., cabergoline + ketoconazole) per clinician judgment.

STEP 4 — Decide

Initiate pituitary-directed medical treatment: cabergoline 0.5–2 mg orally twice weekly (up to 7 mg/week) or pasireotide 600–900 µg subcutaneously twice daily; arrange baseline metabolic panel, glucose, ECG (QT), prolactin, liver function; schedule follow-up UFC or late-night salivary cortisol at 6–12 weeks to assess biochemical control.

Clinical Guardrails / Mimics / Pitfalls

Monitor for hyperglycemia and glycosuria with pasireotide (check fasting glucose q1–2 weeks); assess for GI side effects, gallstones, and QT prolongation; avoid in pregnancy; do not rely solely on UFC if on metyrapone or ketoconazole due to assay interference; watch for adrenal insufficiency when normalizing cortisol; do not use as bridge without planning definitive therapy if applicable.

Concrete Clinical Example

A 50-year-old man with CD, deemed high surgical risk due to severe cardiomyopathy, had persistent hypercortisolism after TSS (UFC 180 µg/24h, normal <45). Baseline HbA1c 6.2%. Started pasireotide 600 µg SC BID. After 8 weeks, UFC 40 µg/24h, HbA1c 6.8%; continued treatment with glucose monitoring and achieved UFC normalization at 4 months.

Source: Treatment of Cushing’s Syndrome: An Endocrine Society Clinical Practice Guideline, Nieman et al., 2015, DOI: 10.1210/jc.2015-1818

レビュー

まだレビューはありません。使ってみた感想をお寄せください。

ログインしてレビューを書く

同じリポジトリのスキル

概要と使いどころ

780g-pump-adjustment

無料

Guide pump setting adjustments for the MiniMed 780G system based on CareLink data, using Medtronic's 3-step follow-up workflow. Use when a clinician has CareLink data for a 780G patient and wants to know what to change — which setting, by how much, and how to program it. Triggers include: "what do I adjust", "how to fix high TIR", "how to reduce hypos", "adjust ICR/ISF/basal", "SmartGuard settings", "780G pump settings review", or any question about optimising 780G therapy after reviewing a download.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

ata-acth-stim-test-interpretation

無料

Performs corticotropin stimulation test to diagnose adrenal insufficiency when morning cortisol is indeterminate (3-15 µg/dL). Triggers include morning cortisol 3-15 µg/dL requiring further AI testing.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

ata-adrenal-crisis-treatment

無料

Administers immediate parenteral injection of 50–100 mg hydrocortisone for suspected adrenal crisis secondary to adrenal insufficiency. Triggers include hypotension, hypoglycemia, or acute illness in a patient with known adrenal insufficiency.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

ata-aed-ai-education

無料

Clinicians educate adrenal insufficiency patients taking nondexamethasone glucocorticoids who initiate enzyme-inducing antiepileptic drugs about early signs of adrenal insufficiency. Trigger when an AI patient on nondexamethasone GC starts an enzyme-inducing AED such as phenytoin, carbamazepine, or oxcarbazepine.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

ata-aed-lt4-monitoring

無料

In central hypothyroidism patients receiving levothyroxine who initiate enzyme‑inducing antiepileptic drugs, the guideline recommends checking free T4 at least 6 weeks after AED start and increasing the levothyroxine dose if free T4 falls below the target range. Triggers include: central hypothyroidism patient on levothyroxine starting antiepileptic drug such as phenytoin, carbamazepine, or oxcarbazepine.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

ata-cortisol-cutoff-ai-diagnosis

無料

Applies serum cortisol cutoffs (<3 μg/dL indicates central adrenal insufficiency; >15 μg/dL likely excludes it) when evaluating morning cortisol for suspected adrenal insufficiency. Triggers include morning cortisol measurement in suspected AI and use when interpreting morning cortisol levels for adrenal insufficiency workup.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

dromlakhani のスキルをすべて見る

このスキルの問題を報告する